RxDoctor Payments Data

Angela Durso, MD

Allergy · Morgantown, PANPI 1194911909

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 41.1% of the total. That places this record below the midpoint for allergy clinicians in PA, where the typical reported total is $1,910.

$1,910in general payments, 2019–2025

Across 31 payments — averaging $61.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$785
  • AstraZeneca$573
  • Genentech USA, Inc.$255
  • Organon$126
  • Sanofi$96
  • Regeneron Healthcare Solutions, Inc.$39
  • plus $37 from 1 others

What the payments were for

  • Food & beverage$1,89799%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,910 in reported general payments places this provider in the 50th percentile of 25 allergy providers in Pennsylvania.

See all allergy providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,853
Medicare patients
69
Services billed
3,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,444
Spiriva RespimatTiotropium Bromide18$13,406
AlvescoCiclesonide24$12,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,616
Breo ElliptaFluticasone/Vilanterol12$4,902
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,183
Azelastine Hcl26$663
Fluticasone Propionate18$527
Famotidine25$191
Montelukast Sodium11$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$573$16,44419 claims
GSKTrelegy Ellipta, Breo Ellipta$785$14,51825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 25 allergy providers in Pennsylvania.

Other allergy in Morgantown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →